access to new drugs

4:30AM
Printer-friendly version
Canadians wait much longer for drugs than Americans and Europeans

Government policies make Canada’s pharmaceutical environment less attractive to drug companies.


10:58AM
Printer-friendly version
New regulations will ultimately deprive Canadians of new medicines

Drug developers are more likely to invest in research and development if prices for their medicines are high.


11:39AM
Printer-friendly version
Delayed drug approvals in Canada—here’s why

New drugs are approved later in Canada than in the United States and European Union.


12:02PM
Printer-friendly version
Mandatory switching of biologic drugs—beware of potential side-effects

Last year, British Columbia became the first province to introduce a mandatory biosimilar switching program for non-medical reasons.


3:03PM
Printer-friendly version
Trudeau government advisors prescribe vast bureaucracy to manage national pharmacare

Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good.


11:41AM
Printer-friendly version
Is Ottawa competent enough to design an efficient and effective national pharmacare program?

A national formulary—essentially a list of drugs—is unlikely to match the comprehensive lists covered by private insurance plans.